Lani Morvan - Zealand Pharma Investor Officer
| ZLDPF Stock | USD 99.52 4.53 4.35% |
Insider
Lani Morvan is Investor Officer of Zealand Pharma AS
| Phone | 45 88 77 36 00 |
| Web | https://www.zealandpharma.com |
Zealand Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4816) % which means that it has lost $0.4816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4412) %, meaning that it generated substantial loss on money invested by shareholders. Zealand Pharma's management efficiency ratios could be used to measure how well Zealand Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pharis Mohideen | DBV Technologies | 59 | |
| Saurabh MD | Centessa Pharmaceuticals PLC | 48 | |
| Annie Neild | NewAmsterdam Pharma | N/A | |
| Vladimir MD | Biohaven Pharmaceutical Holding | 53 | |
| Pascal Wotling | DBV Technologies | N/A | |
| William Jones | Biohaven Pharmaceutical Holding | 57 | |
| Louise Kooij | NewAmsterdam Pharma | 48 | |
| BS CPA | Inhibrx | 42 | |
| MD MBA | Opthea | N/A | |
| Robert Kramer | Portage Biotech | N/A | |
| Kishen Mehta | Biohaven Pharmaceutical Holding | 35 | |
| Joseph Ciavarella | Portage Biotech | N/A | |
| Clifford MS | Biohaven Pharmaceutical Holding | N/A | |
| Nicki Vasquez | Sutro Biopharma | 61 | |
| William JD | Sutro Biopharma | 66 | |
| Allan CPA | Portage Biotech | 60 | |
| FACC Facc | NewAmsterdam Pharma | 65 | |
| Daniel Tass | DBV Technologies | 64 | |
| Matthew Robinson | Immunome | N/A | |
| MD MBA | Portage Biotech | 56 | |
| James Goding | Opthea | N/A | |
Management Performance
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 |
Zealand Pharma AS Leadership Team
Elected by the shareholders, the Zealand Pharma's board of directors comprises two types of representatives: Zealand Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zealand. The board's role is to monitor Zealand Pharma's management team and ensure that shareholders' interests are well served. Zealand Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zealand Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henriette Wennicke, Chief Officer | ||
| Lani Morvan, Investor Officer | ||
| Hanne Bak, Sr. Director | ||
| Adam MD, Pres CEO | ||
| Mads Kronborg, Head Communication | ||
| Ravinder Chahil, Sr Counsel | ||
| Danilo Verge, Head Affairs | ||
| Christina Bredal, VP Organization | ||
| Ivan Moller, Chief Officer | ||
| Jens MD, Head Pharmacology |
Zealand Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Zealand Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 51.28 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Price To Earning | 4.03 X | |||
| Price To Book | 27.79 X | |||
| Price To Sales | 5.19 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.